- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer
January 31st 2025, 9:29pm
Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.
Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers
January 31st 2025, 8:39pm
Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.
PPP2R1A Mutations Associated With Prolonged OS in High-Risk Endometrial Cancer
January 31st 2025, 8:00pm
OS outcomes with lenvatinib plus pembrolizumab were prolonged in patients with PPP2R1A-mutated vs wild-type high-risk endometrial cancer.
High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma
January 31st 2025, 2:54am
High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.
Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor
January 31st 2025, 1:48am
R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.
Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH
January 31st 2025, 12:48am
Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
January 30th 2025, 10:42pm
The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer
January 30th 2025, 10:23pm
An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.
T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer
January 29th 2025, 10:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
T-DM1 was found to be tolerable, but progression-free survival was not improved vs historical data in HER2-positive biliary tract cancer.
OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer
January 28th 2025, 9:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
January 28th 2025, 2:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.
Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer
January 27th 2025, 8:57pm
Gastrointestinal Cancers Symposium (ASCO GI)
Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.
Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC
January 27th 2025, 6:41pm
A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.
Fruquintinib Plus TAS-102 Demonstrates Efficacy and Acceptable Toxicity in Pretreated mCRC
January 27th 2025, 6:20pm
Gastrointestinal Cancers Symposium (ASCO GI)
Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.
Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium
January 27th 2025, 1:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.
Signatera ctDNA Assay Found to Influence Adjuvant Chemo Decision-Making in Stage II/III CRC
January 26th 2025, 11:00am
Gastrointestinal Cancers Symposium (ASCO GI)
Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.
Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC
January 26th 2025, 12:36am
Gastrointestinal Cancers Symposium (ASCO GI)
Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.
Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer
January 26th 2025, 12:35am
Gastrointestinal Cancers Symposium (ASCO GI)
Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.
Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC
January 25th 2025, 11:55pm
Gastrointestinal Cancers Symposium (ASCO GI)
Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.
Nivolumab Plus Ipilimumab Prolongs PFS vs Nivolumab Alone in MSI-H/dMMR mCRC
January 25th 2025, 11:50pm
Gastrointestinal Cancers Symposium (ASCO GI)
Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.